NGOs urge end to US-backed Gaza aid distribution system
JERUSALEM - A group of 169 aid organisations called for an end to a US- and Israeli-backed aid distribution scheme in Gaza after repeated reports of people being killed while seeking rations.
The non-governmental organisations urged a return to the UN-led aid mechanism that existed in the war-torn territory until March, when Israel imposed a full blockade on humanitarian assistance entering Gaza during an impasse in truce talks with Palestinian militant group Hamas.
'NGOs call for immediate action to end the deadly Israeli distribution scheme (including the so-called Gaza Humanitarian Foundation) in Gaza,' the organisations wrote in a joint statement on June 30 .
They urged action to 'revert to the existing UN-led coordination mechanisms, and lift the Israeli government's blockade on aid and commercial supplies'.
The US- and Israeli-backed Gaza Humanitarian Foundation (GHF) has been tasked with distributing aid in the Palestinian territory since late May, when the two-month blockade was partially eased after mounting international condemnation and warnings of imminent famine.
GHF operations have since been marred by chaotic scenes and near-daily reports of Israeli forces firing on those waiting to collect rations in the territory, where the Israeli military is seeking to destroy Hamas.
The signatories to the June 30 statement included NGOs from Europe, the United States and Israel working in medical assistance, hunger relief, development and human rights.
They said more than 500 Palestinians were killed and almost 4,000 injured while trying to access or distribute food in less than four weeks. The Hamas-ruled territory's health ministry has given similar figures.
'Under the Israeli government's new scheme, starved and weakened civilians are being forced to trek for hours through dangerous terrain and active conflict zones, only to face a violent, chaotic race to reach fenced, militarised distribution sites,' the statement read.
Aid distribution in Gaza was traditionally coordinated through various NGOs and UN agencies, notably the UN agency for Palestinian refugees UNRWA, which had 13,000 staff in the coastal enclave before the war.
Israel said it tasked GHF with distribution in Gaza to keep Hamas from controlling the flow of aid.
The Israeli military last week denied a newspaper report that cited Israeli soldiers as saying they had been ordered to fire at civilians near aid centres.
It said in a statement that it was 'operating to allow and facilitate the distribution of humanitarian aid' by GHF, 'and to secure the routes leading to the distribution centers, in order to allow the aid to reach the civilians rather than Hamas'.
It added that it was examining 'reports of incidents of harm to the civilians approaching the distribution centres'. AFP
Join ST's Telegram channel and get the latest breaking news delivered to you.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
a day ago
- Straits Times
NGOs urge end to US-backed Gaza aid distribution system
The non-governmental organisations urged a return to the UN-led aid mechanism that existed in the war-torn territory until March. PHOTO: AFP JERUSALEM - A group of 169 aid organisations called for an end to a US- and Israeli-backed aid distribution scheme in Gaza after repeated reports of people being killed while seeking rations. The non-governmental organisations urged a return to the UN-led aid mechanism that existed in the war-torn territory until March, when Israel imposed a full blockade on humanitarian assistance entering Gaza during an impasse in truce talks with Palestinian militant group Hamas. 'NGOs call for immediate action to end the deadly Israeli distribution scheme (including the so-called Gaza Humanitarian Foundation) in Gaza,' the organisations wrote in a joint statement on June 30 . They urged action to 'revert to the existing UN-led coordination mechanisms, and lift the Israeli government's blockade on aid and commercial supplies'. The US- and Israeli-backed Gaza Humanitarian Foundation (GHF) has been tasked with distributing aid in the Palestinian territory since late May, when the two-month blockade was partially eased after mounting international condemnation and warnings of imminent famine. GHF operations have since been marred by chaotic scenes and near-daily reports of Israeli forces firing on those waiting to collect rations in the territory, where the Israeli military is seeking to destroy Hamas. The signatories to the June 30 statement included NGOs from Europe, the United States and Israel working in medical assistance, hunger relief, development and human rights. They said more than 500 Palestinians were killed and almost 4,000 injured while trying to access or distribute food in less than four weeks. The Hamas-ruled territory's health ministry has given similar figures. 'Under the Israeli government's new scheme, starved and weakened civilians are being forced to trek for hours through dangerous terrain and active conflict zones, only to face a violent, chaotic race to reach fenced, militarised distribution sites,' the statement read. Aid distribution in Gaza was traditionally coordinated through various NGOs and UN agencies, notably the UN agency for Palestinian refugees UNRWA, which had 13,000 staff in the coastal enclave before the war. Israel said it tasked GHF with distribution in Gaza to keep Hamas from controlling the flow of aid. The Israeli military last week denied a newspaper report that cited Israeli soldiers as saying they had been ordered to fire at civilians near aid centres. It said in a statement that it was 'operating to allow and facilitate the distribution of humanitarian aid' by GHF, 'and to secure the routes leading to the distribution centers, in order to allow the aid to reach the civilians rather than Hamas'. It added that it was examining 'reports of incidents of harm to the civilians approaching the distribution centres'. AFP Join ST's Telegram channel and get the latest breaking news delivered to you.
Independent Singapore
a day ago
- Independent Singapore
Trump's aid slash triggers global death forecast: 14 million lives at risk, Lancet finds
A group of African women and children (for illustration purposes only) PARIS, FRANCE: A new study revealed that more than 14 million people, many of them young children, could perish by 2030 because of deep cuts in U.S. foreign assistance. The study, published in The Lancet and featured in the latest Inquirer report, was released as world leaders assemble in Seville, Spain, for a key United Nations (UN) aid conference. It presented the possible repercussions of the Trump administration's decision to demolish the U.S. Agency for International Development (USAID). 'For vulnerable populations, this is a shock on par with a global pandemic or major war,' said co-author Davide Rasella of the Barcelona Institute for Global Health. By making use of data from 133 nations and cutting-edge modelling methods, researchers estimate that the USAID subsidy aided in preventing 91 million deaths between 2001 and 2021, but with U.S. foreign assistance now reduced by 83%, development could be hard hit, principally in health systems across low- and middle-income countries. Millions of children at risk as health gains reversed The anticipated human toll is confounding — more than 4.5 million children under five are projected to die in the next five years because of the sudden aid reductions, approximately 700,000 young lives lost every year. The range is comparable to the death statistics of World War I, researchers said. Initiatives supported by USAID had reduced child mortality by 32% and all-cause mortality by 15%, with sharp drops in deaths from HIV/AIDS, malaria, and neglected tropical diseases. The decommissioning of USAID came weeks after Donald Trump's return to the White House in January, with his then-advisor Elon Musk bragging that the agency had been put 'through the woodchipper.' In the months since, key European benefactors — Germany, France, and the UK — have also restructured their aid pledges, worsening the predicament. Global leaders meet in Spain, but the U.S. stays away The alarming report comes as many of the world's leaders and influential business 'crème de la crème' converge in Seville for the biggest aid-focused conference in a decade. Yet, the United States, historically the single major donor to worldwide charitable aid, is conspicuously absent. Before the reductions, USAID accounted for just 0.3% of the federal budget — roughly 17 cents per American per day. 'Now is the time to scale up, not scale back,' Rasella admonished. Fellow study author James Macinko of UCLA echoed the sentiment, stressing how far tiny donations can go: 'If people realized that US$64 (S$81) a year could help save millions of lives, I believe they'd want to keep this lifeline going.' While the forecasts are ugly, researchers underscore that these are not irrevocable. With transformed political resolve and financial backing, much of the damage could still be avoided.
Straits Times
2 days ago
- Straits Times
First China weight loss drug emerges
Obesity drugmakers Novo Nordisk and Eli Lilly & Co. now face their first serious rival in China. PHOTO: REUTERS Hong Kong – Novo Nordisk and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their first serious rival in China. Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide, a turning point in China's efforts to combat rising obesity and diabetes rates with local innovation. With over 600 million Chinese adults projected to be overweight by 2050, the emergence of a viable local alternative to Novo and Lilly's blockbuster GLP-1 treatments could make weight loss drugs more accessible in the world's second-largest economy. China's nascent weight loss drug market is poised for rapid growth, with analysts estimating it could grow to between US$5.6 billion (S$7.2 billion) and US$11.4 billion a year. While China still accounts for just a fraction of the projected US$150 billion global pie, a raft of homegrown treatments and cheaper generics could significantly improve the availability – and affordability – of the medication. The country has a pipeline of more than 30 late-stage obesity drug candidates under development, according to LEK Consulting. Several firms have already licensed their drugs to US or European drugmakers like AstraZeneca and Merck & Co for further clinical development outside the country. Local biotech firms are promising to overcome the limitations of current treatments, including creating long-awaited GLP-1 pills that are just as effective and safe as weekly injections peddled by Novo and Lilly. Leading insulin producer Gan & Lee Pharmaceutical is pushing ahead a longer-acting drug that can be taken every two weeks, instead of weekly. Laekna is developing a treatment that would help patients preserve more muscle – a common concern among GLP-1 takers – while still losing fat. Hangzhou Sciwind Biosciences expects China will approve its drug ecnoglutide, which led to more than 15 per cent weight loss after 48 weeks when given at the highest dose, in early 2026. 'Multiple Chinese biopharma are developing differentiated and competitive candidates and have the potential to lead the direction of weight loss drug research and development,' said Chen Chen, head of China healthcare research at UBS Securities. Competition is expected to ramp up next year when cheaper alternative versions of semaglutide – the active ingredient in Novo's Wegovy – launch after semaglutide's China patent expires. Their emergence could pressure drugmakers to lower their treatment prices, and could quickly expand access to the drugs across a country of 1.4 billion people. Compared to Western countries where popular GLP-1 drugs are widely available for people looking to lose weight, the current penetration rate for such drugs in China is 'extremely low,' said UBS's Mr Chen. Novo only started rolling out obesity treatments in China in 2024, and Lilly earlier this year. A government-led campaign to curb obesity and establish new weight management clinics has fuelled demand, which is now outstripping supply and leading to stock shortages, said Shawn Qu, chief of SinoUnited Health's Endocrinology, Metabolism and Thyroid Center in Shanghai. 'It's far from meeting the clinical need,' said Mr Qu, who's also an adviser to China's National Health Commission weight management committee. Foreign medicines have long enjoyed higher trust and recognition in China, where the local biotech industry is still overcoming past quality issues. Skepticism about the quality of domestic generic medicines also remains high among Chinese – and rare backlash from doctors earlier this year fuelled questions about whether government efforts to slash treatment prices had come at the cost of efficacy. The relative price differences between foreign and domestic weight loss drugs could be much smaller than in PD-(L)1 medicines used to treat cancer, added Yang Huang, senior analyst for China healthcare research at JP Morgan. 'We think foreign companies could be more willing to lower prices for their weight loss drugs in China,' he said, 'as we have seen in the US market where major weight loss drug players have started engaging in price competition.' Going forward, 'you'll see a lot more competitors in the China market versus anywhere else,' said Justin Wang, head of LEK's China practice. 'It will be unlikely for one or two companies to dominate the whole market.' BLOOMBERG Join ST's Telegram channel and get the latest breaking news delivered to you.
